EGFR and ovarian cancer: For example, the EGFR inhibitor erlotinib sensitized EGFR-overexpressing TNBC cells to doxorubicin [43], whereas low dose metformin or the TopoI inhibitor SN38 increased the DNA damage response in ovarian cancer cells [44].